Immunocompromised patients with HBsAg a Determinant Mutants: Comparison of HBsAg diagnostic assays

Intervirology

Volumn 53, Issue 3, 2010, Pages 183-187

  Veropalumbo, E ^a   Marrone, A ^d   Vallefuoco, L ^a   Perruolo, G ^a   Orlando, R ^b   Scordino, F ^b   Tosone, G ^b   Zampino, R ^d   Trani, B ^d   Genovese, A ^c   Spadaro, G ^c   D'orio, C ^c   Portella, G ^a  

^a Servizio di Patologia Clinica   (Italy)

^b Clinica Malattie Infettive   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

G145R; Hepatitis B surface antigen assay; Hepatitis B virus a determinant mutant; Immuncompromised host; P120L; T123N

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; LAMIVUDINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; ASSAY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HEPATITIS B VIRUS; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN DEFICIENCY; KIDNEY GRAFT; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SPLENECTOMY; VIRUS LOAD; VIRUS MUTATION; VIRUS REACTIVATION;

AGED; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOASSAY; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MUTATION, MISSENSE; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 77449104078     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000289342     Document Type: Article

References (17)

1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP: Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-125. (Pubitemid 44289094)
2. Bartholomeusz A, Tehan BG, Chalmers DK: Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9: 149-160. (Pubitemid 38560208)
3. Pawlotsky JM: The concept of hepatitis B virus mutant escape. J Clin Virol 2005; 34 (suppl 1):S125-S129.
4. Zoulim F: Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 1-15. (Pubitemid 39307089)
5. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-591. (Pubitemid 19216208)
6. Carman WF: The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4(suppl 1):11-20.
7. Protzer-Knolle U, Naumann U, Bar tenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH: Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254-263. (Pubitemid 28041562)
8. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R: Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345: 1406-1407.
9. Gerlich WH: Diagnostic problems caused by HBsAg mutants - a consensus report of an expert meeting. Intervirology 2004; 47: 310-313.
10. Weber B: Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005; 32: 102-112. (Pubitemid 40093960)
11. Echevarría JM, Avellón A: Hepatitis B virus genetic diversity. J Med Virol 2006; 78(suppl 1):S36-S42. (Pubitemid 43993463)
12. Awerkiew S, Daumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH: Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38: 83-86. (Pubitemid 44881426)
13. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N: Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 3: 599-608. (Pubitemid 40723731)
14. Ly TD, Servant-Delmas A, Bagot S, Gonzalo S, Ferey MP, Ebel A, Dussaix E, Laperche S, Roque-Afonso AM: Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006; 44: 2321-2326. (Pubitemid 44092392)
15. Scheiblauer H, Soboll H, Nick S: Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 2006; 78:S66-S70. (Pubitemid 43993469)
16. Echevarria JM, Avellon A: Improved detection of natural hepatitis B virus surface antigen (HBsAg) mutants by a new version of the Vitros HBsAg assay. J Med Virol 2008; 80: 598-602. (Pubitemid 351358555)
17. Colson P, Borentain P, Motte A, Henry M, Moal V, Botta-Fridlund D, Tamalet C, Gérolami R: Clinical and virological significance of the co-existence of HBsAg and anti- HBs antibodies in hepatitis B chronic carriers. Virology 2007; 367: 30-40. (Pubitemid 47418929)